Draft Amendment: MHLW Designation of Drugs Requiring Testing under Pharmaceuticals and Medical Devices Act (Art. 43(1))
医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第四十三条第一項の規定に基づき検査を要するものとして厚生労働大臣の指定する医薬品等の一部を改正する件（案）に関する御意見の募集について
Published: 2026-07-03 · Source: e-Gov Public Comment · Stage: Public Comment Closed · Area: Healthcare / Pharmaceuticals · Impact (preliminary): Medium · Comment deadline: 2026-08-02 00:00 JST · First detected by this dashboard: 2026-07-05
View the original Japanese source More Healthcare / Pharmaceuticals updates Search all updates in the dashboard
AI summary
Generated by AI from the Japanese source metadata. It is an unofficial monitoring aid, not legal advice, and may contain errors. The area, stage, and impact labels are preliminary keyword-based triage labels. Confirm every point in the original Japanese source.
Summary
The Ministry of Health, Labour and Welfare (MHLW) has published a draft (proposed) amendment to its designation of pharmaceuticals and similar products that require testing under Article 43, Paragraph 1 of the Act on Securing Quality, Efficacy and Safety of Pharmaceuticals and Medical Devices. The draft was announced on 2026-07-03 and public comments were accepted until 2026-08-02. The inquiry contact is the Inspection and Narcotics Control Division of the Pharmaceutical Affairs Bureau, MHLW.
Business Impact
If adopted, the amendment could change which pharmaceuticals or related products are subject to testing requirements, which may be relevant to manufacturers and importers. The specific scope and effect cannot be determined from the provided metadata.
Recommended Action
Review the official Japanese announcement and the attached draft text on e-Gov to confirm which products are affected and whether the comment period has closed or the outcome has been published.